Prehospital Tranexamic Acid for Severe Trauma. PATCH-Trauma Investigators, Group, t. A. C. T., Gruen, R. L., Mitra, B., Bernard, S. A., McArthur, C. J., Burns, B., Gantner, D. C., Maegele, M., Cameron, P. A., Dicker, B., Forbes, A. B., Hurford, S., Martin, C. A., Mazur, S. M., Medcalf, R. L., Murray, L. J., Myles, P. S., Ng, S. J., Pitt, V., Rashford, S., Reade, M. C., Swain, A. H., Trapani, T., & Young, P. J. The New England Journal of Medicine, 389(2):127–136, July, 2023.
doi  abstract   bibtex   
BACKGROUND: Whether prehospital administration of tranexamic acid increases the likelihood of survival with a favorable functional outcome among patients with major trauma and suspected trauma-induced coagulopathy who are being treated in advanced trauma systems is uncertain. METHODS: We randomly assigned adults with major trauma who were at risk for trauma-induced coagulopathy to receive tranexamic acid (administered intravenously as a bolus dose of 1 g before hospital admission, followed by a 1-g infusion over a period of 8 hours after arrival at the hospital) or matched placebo. The primary outcome was survival with a favorable functional outcome at 6 months after injury, as assessed with the use of the Glasgow Outcome Scale-Extended (GOS-E). Levels on the GOS-E range from 1 (death) to 8 ("upper good recovery" [no injury-related problems]). We defined survival with a favorable functional outcome as a GOS-E level of 5 ("lower moderate disability") or higher. Secondary outcomes included death from any cause within 28 days and within 6 months after injury. RESULTS: A total of 1310 patients were recruited by 15 emergency medical services in Australia, New Zealand, and Germany. Of these patients, 661 were assigned to receive tranexamic acid, and 646 were assigned to receive placebo; the trial-group assignment was unknown for 3 patients. Survival with a favorable functional outcome at 6 months occurred in 307 of 572 patients (53.7%) in the tranexamic acid group and in 299 of 559 (53.5%) in the placebo group (risk ratio, 1.00; 95% confidence interval [CI], 0.90 to 1.12; P = 0.95). At 28 days after injury, 113 of 653 patients (17.3%) in the tranexamic acid group and 139 of 637 (21.8%) in the placebo group had died (risk ratio, 0.79; 95% CI, 0.63 to 0.99). By 6 months, 123 of 648 patients (19.0%) in the tranexamic acid group and 144 of 629 (22.9%) in the placebo group had died (risk ratio, 0.83; 95% CI, 0.67 to 1.03). The number of serious adverse events, including vascular occlusive events, did not differ meaningfully between the groups. CONCLUSIONS: Among adults with major trauma and suspected trauma-induced coagulopathy who were being treated in advanced trauma systems, prehospital administration of tranexamic acid followed by an infusion over 8 hours did not result in a greater number of patients surviving with a favorable functional outcome at 6 months than placebo. (Funded by the Australian National Health and Medical Research Council and others; PATCH-Trauma ClinicalTrials.gov number, NCT02187120.).
@article{patch-trauma_investigators_and_the_anzics_clinical_trials_group_prehospital_2023,
	title = {Prehospital {Tranexamic} {Acid} for {Severe} {Trauma}},
	volume = {389},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2215457},
	abstract = {BACKGROUND: Whether prehospital administration of tranexamic acid increases the likelihood of survival with a favorable functional outcome among patients with major trauma and suspected trauma-induced coagulopathy who are being treated in advanced trauma systems is uncertain.
METHODS: We randomly assigned adults with major trauma who were at risk for trauma-induced coagulopathy to receive tranexamic acid (administered intravenously as a bolus dose of 1 g before hospital admission, followed by a 1-g infusion over a period of 8 hours after arrival at the hospital) or matched placebo. The primary outcome was survival with a favorable functional outcome at 6 months after injury, as assessed with the use of the Glasgow Outcome Scale-Extended (GOS-E). Levels on the GOS-E range from 1 (death) to 8 ("upper good recovery" [no injury-related problems]). We defined survival with a favorable functional outcome as a GOS-E level of 5 ("lower moderate disability") or higher. Secondary outcomes included death from any cause within 28 days and within 6 months after injury.
RESULTS: A total of 1310 patients were recruited by 15 emergency medical services in Australia, New Zealand, and Germany. Of these patients, 661 were assigned to receive tranexamic acid, and 646 were assigned to receive placebo; the trial-group assignment was unknown for 3 patients. Survival with a favorable functional outcome at 6 months occurred in 307 of 572 patients (53.7\%) in the tranexamic acid group and in 299 of 559 (53.5\%) in the placebo group (risk ratio, 1.00; 95\% confidence interval [CI], 0.90 to 1.12; P = 0.95). At 28 days after injury, 113 of 653 patients (17.3\%) in the tranexamic acid group and 139 of 637 (21.8\%) in the placebo group had died (risk ratio, 0.79; 95\% CI, 0.63 to 0.99). By 6 months, 123 of 648 patients (19.0\%) in the tranexamic acid group and 144 of 629 (22.9\%) in the placebo group had died (risk ratio, 0.83; 95\% CI, 0.67 to 1.03). The number of serious adverse events, including vascular occlusive events, did not differ meaningfully between the groups.
CONCLUSIONS: Among adults with major trauma and suspected trauma-induced coagulopathy who were being treated in advanced trauma systems, prehospital administration of tranexamic acid followed by an infusion over 8 hours did not result in a greater number of patients surviving with a favorable functional outcome at 6 months than placebo. (Funded by the Australian National Health and Medical Research Council and others; PATCH-Trauma ClinicalTrials.gov number, NCT02187120.).},
	language = {eng},
	number = {2},
	journal = {The New England Journal of Medicine},
	author = {{PATCH-Trauma Investigators and the ANZICS Clinical Trials Group} and Gruen, Russell L. and Mitra, Biswadev and Bernard, Stephen A. and McArthur, Colin J. and Burns, Brian and Gantner, Dashiell C. and Maegele, Marc and Cameron, Peter A. and Dicker, Bridget and Forbes, Andrew B. and Hurford, Sally and Martin, Catherine A. and Mazur, Stefan M. and Medcalf, Robert L. and Murray, Lynnette J. and Myles, Paul S. and Ng, Sze J. and Pitt, Veronica and Rashford, Stephen and Reade, Michael C. and Swain, Andrew H. and Trapani, Tony and Young, Paul J.},
	month = jul,
	year = {2023},
	pmid = {37314244},
	keywords = {Adult, Antifibrinolytic Agents, Australia, Blood Coagulation Disorders, Emergency Medical Services, Humans, Tranexamic Acid, Vascular Diseases, Wounds and Injuries},
	pages = {127--136},
}
Downloads: 0
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021